**Summary: Low activity**

The seasonal influenza activity level in Manitoba overall is low. Locally acquired influenza A(H3) infections have been reported this week. Visits to Emergency Department due to Influenza-Like-Illness (ILI) have been increasing since September. Rhinovirus has been the most commonly detected respiratory virus recently.

Nationally, influenza activity remains at interseasonal levels. Some areas have reported an increasing activity. The percentage of laboratory tests positive for influenza remains higher for this time of year compared to previous seasons. Influenza associated hospitalizations and regions with sporadic or clustered cases are in the higher range of expected levels.

For the 2017–2018 influenza season in Manitoba, two quadrivalent inactivated vaccines and one quadrivalent live attenuated influenza vaccine are available through the provincial Publicly-Funded Seasonal Influenza Immunization Program. Quadrivalent influenza vaccines protect people from four influenza strains. People 65 years of age or older who are living in long-term care facilities are eligible to receive the high-dose vaccine.

### Laboratory

Laboratory-confirmed influenza cases:
- This week:  
  - Influenza A cases: 3  
  - Influenza B cases: 0
- Since Sept. 1, 2017:  
  - Influenza A cases: 4  
  - Influenza B cases: 0

### Severity

Severe outcomes associated with laboratory-confirmed diagnosis of influenza:
- This week:  
  - ICU* admissions: 0  
  - Deaths: 0
- Since Sept. 1, 2017:  
  - ICU* admissions: 0  
  - Deaths: 0

### Outbreak

Laboratory-confirmed Influenza outbreaks:
- This week:  
  - Influenza A outbreaks: 0  
  - Influenza B outbreaks: 0
- Since Sept. 1, 2017:  
  - Influenza A outbreaks: 0  
  - Influenza B outbreaks: 0

### ILI in Community

Calls to Influenza Service at Health Links–Info Santé this week: 69

### ILI in Medical Care

Visits to sentinel physicians due to ILI this week: 3.9%

Units of Antiviral dispensed from community retail pharmacies: N/A

### ILI in Emergency Department

ILI patients in Emergency Department this week: 137

### Immunization

As of Oct. 28, 2017:  
- Percent of total influenza vaccine doses ordered from manufacturers received by MHSAL: 96.5%  
- Percent of total doses ordered by immunization service providers shipped from MHSAL across Manitoba: 80.5%

### Antiviral Susceptibility

Isolates resistant to antiviral since Sept. 1, 2017 in Manitoba:  
- Oseltamivir: 0  
- Zanamivir: 0

### Regional Health Authority

Cases since Sept. 1, 2017:  
- Winnipeg: 3  
- Southern: 0  
- Interlake-Eastern: 0  
- Prairie Mountain: 1  
- Northern: 0

**Note.** * ICU admissions were also included in hospitalizations.

Time trends in this report were analyzed by **epidemiology week**.

Numbers are subject to change. Missed events in the current report due to a delay of submission to MHSAL will be included in later reports when data become available.
Figure 5. Weekly ILI Visits to Emergency Rooms and % of Total, Manitoba, 2017-2018

Figure 6. Weekly Total and ILI Visits to Emergency Rooms, Manitoba
### Table 1. Antiviral Resistance of Isolates by Influenza Type and Subtype Since September 1, 2017–2018

<table>
<thead>
<tr>
<th></th>
<th>Oseltamivir</th>
<th>Zanamivir</th>
<th>Amantadine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Resistant</td>
<td>Sensitive</td>
<td>Resistant</td>
</tr>
<tr>
<td><strong>Canada</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>0</td>
<td>34</td>
<td>0</td>
</tr>
<tr>
<td>A(H1N1)</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>B</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td><strong>Manitoba</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>A(H1N1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

N/A = Not applicable

### Table 2. Influenza Strain Characterization reported by NML since September 1, 2017, 2017–2018

<table>
<thead>
<tr>
<th>Strain</th>
<th>Number of viruses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>A/Hong Kong/4801/2014 (H3N2)-like</td>
<td>5</td>
</tr>
<tr>
<td>A/Michigan/45/2015 (H1N1)-like</td>
<td>5</td>
</tr>
<tr>
<td>B/Brisbane/60/2008-like</td>
<td>1</td>
</tr>
<tr>
<td>B/Phuket/3073/2013-like</td>
<td>5</td>
</tr>
</tbody>
</table>

Since September 1, 2017, NML has characterized 49 influenza A and B viruses.

1. **38 influenza A(H3N2) viruses:**
   - 5 influenza A (H3N2) viruses were antigenically characterized as A/Hong Kong/4801/2014, the influenza A/H3N2 component of the 2017-2018 Northern Hemisphere influenza vaccine. In those 5 viruses, 4 belonged to genetic group 3C.2a and 1 belonged to subclade group 3C.2a1.
   - 33 influenza A(H3N2) viruses did not grow to sufficient hemagglutination titers for antigenic characterization by hemagglutination inhibition assays. Therefore, genetic characterization was performed. Sequence analysis of the HA gene of these viruses showed that 23 H3N2 viruses belonged to genetic group 3C.2a and 10 belonged to subclade 3C2a1. A/Hong Kong/4801/2014(H3N2)-like virus, the vaccine strain, belongs to genetic group 3C.2a.

2. **5 influenza A(H1N1) viruses:**
   - 5 influenza A(H1N1) viruses characterized were antigenically similar to A/Michigan/45/2015, the influenza A(H1N1) component in the vaccine.

3. **6 influenza B viruses:**
   - 1 influenza B viruses were characterized as B/Brisbane/60/2008-like (Victoria lineage), the influenza B component in the quadrivalent vaccine.
   - 5 influenza B viruses characterized were antigenically similar to B/Phuket/3073/2013 (Yamagata lineage), the influenza B component in the vaccine.
Epidemiology and Surveillance
Manitoba Health, Seniors and Active Living
flusurveillance@gov.mb.ca
(204)786-7335

Other Epidemiology and Surveillance reports
http://www.gov.mb.ca/health/publichealth/surveillance/index.html

National Influenza Surveillance
Appendix

Data Sources

Laboratory Surveillance

Reports of influenza nucleic acid detection, culture isolation, and enzyme immunoassay (EIA) detections are received from Cadham Provincial Laboratory (CPL) and occasionally other laboratories. These reports are forwarded to Epidemiology and Surveillance (E&S) within 24 hours of confirmation. CPL also performs testing for other respiratory viruses including parainfluenza, RSV, adenovirus, rhinovirus, coronavirus, enterovirus, and bocavirus, which are reported to E&S on a weekly basis.

Outbreak

Outbreaks are reported to E&S by a phone call or email from public health staff within Regional Health Authorities (RHAs) or from CPL advising the assignment of an outbreak code. CPL submits both positive and negative laboratory results related to outbreaks to E&S. Outbreak investigations are reported from RHAs to E&S by completing an outbreak summary report form on paper or electronically through the Canadian Network for Public Health Intelligence (CNPHI).

Health Links – Info Santé

Health Links–Info Santé is a 24-hour, 7-days a week telephone information service. It is staffed by registered nurses with the knowledge to provide answers to health care questions and guidance to appropriate care over the phone. When a caller phones Health Links–Info Santé and selects Influenza Service, they are given an option to select information on (1) the groups of individuals who are at an increased risk of serious illness, (2) how to arrange an influenza vaccine, (3) the annual influenza immunization campaign, or (4) the management of influenza and its potential complications.

ILI visits to sentinel physicians

Manitoba participates in FluWatch, the Canada’s national surveillance system co-ordinated by Public Health Agency of Canada (PHAC), which monitors the spread of influenza and ILI on a year-round basis. FluWatch consists of a network of laboratories, hospitals, doctor’s offices and provincial and territorial ministries of health. In 2017–2018, there are 19 sentinel physicians recruited throughout Manitoba reporting to FluWatch weekly. E&S receives weekly reports from FluWatch which present the ILI rate for Manitoba and for each of the participating sentinel physicians. Note that the reporting sentinel physicians are different by week and their reports may not be representative of ILI activity across the province.

Antiviral dispensing

The units of antiviral drug, Oseltamivir and Zanamivir, dispensed from community retail pharmacies since beginning of October to Manitoba residents during the influenza season are reported to E&S from Drug Programs Information Network (DPIN) on a weekly basis. Antiviral drugs dispensed to in-patients or through nursing stations could not be included in this report due to lack of data.

ILI visits to Emergency Rooms

Daily statistics of ILI related visits to Emergency Department (ED) at Winnipeg Regional Health Authority (WRHA) are submitted to E&S weekly. ILI cases are defined as patients whose triage chief complaints contain either of these symptoms: weakness, shortness of breath, cough, headache, fever, cardiac/respiratory arrest, sore throat, and upper respiratory tract infection complaints.
Antiviral Resistance

Influenza and Respiratory Viruses Section of National Microbiology Laboratory (NML) undertakes enhanced surveillance, investigations, and research on influenza and other respiratory pathogens. A random sample of positive influenza specimens isolated by culture is referred from each provincial laboratory to NML for strain characterization and antiviral resistance testing. The aggregate level information is then shared with provinces and territories on a weekly basis.

Circulating Strain

NML antigenically characterizes influenza viruses received from Canadian laboratories year-round. In Manitoba, a random sample of positive influenza specimens isolated by culture is referred from CPL to NML for strain characterization.

Immunization Program

As per World Health Organization (WHO), all seasonal quadrivalent influenza vaccines for 2017–2018 in the northern hemisphere contain:

- A/Hong Kong/4801/2014 (H3N2)-like virus (in trivalent vaccine)
- A/Michigan/45/2015 (H1N1)pdm09-like virus (in trivalent vaccine)
- B/Brisbane/60/2008-like virus (in trivalent vaccine)
- B/Phuket/3073/2013-like virus

For the 2017–2018 influenza season, MHSAL has been allotted the quadrivalent inactivated vaccines (QIV), Fluzone® Quadrivalent (Sanofi Pasteur) and FluLaval Tetra® (GlaxoSmithKline), and the quadrivalent live attenuated influenza vaccine (QLAIV) FluMist® Quadrivalent (AstraZeneca), as part of the province’s Publicly-Funded Seasonal Influenza Immunization Program.

This year, a new seasonal influenza vaccine, Fluzone® High-Dose, is offered to people 65 years of age or older that are living in long-term care facilities (LTCF) in Manitoba. This vaccine is a trivalent inactivated vaccine (TIV) and contains four times the amount of influenza virus antigen per strain compared to the standard-dose influenza vaccine. Therefore, this vaccine is expected to provide better protection against seasonal influenza compared to the standard-dose vaccine.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPL</td>
<td>Cadham Provincial Laboratory</td>
</tr>
<tr>
<td>CNPHI</td>
<td>Canadian Network for Public Health Intelligence</td>
</tr>
<tr>
<td>E&amp;S</td>
<td>Epidemiology and Surveillance</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza-Like-Illness</td>
</tr>
<tr>
<td>LTCF</td>
<td>Long Term Care Facility</td>
</tr>
<tr>
<td>MHSAL</td>
<td>Manitoba Health, Seniors and Active Living</td>
</tr>
<tr>
<td>NML</td>
<td>National Microbiology Laboratory</td>
</tr>
<tr>
<td>PHAC</td>
<td>Public Health Agency of Canada</td>
</tr>
<tr>
<td>RHA</td>
<td>Regional Health Authority</td>
</tr>
<tr>
<td>RSV</td>
<td>Respiratory Syncytial Virus</td>
</tr>
<tr>
<td>WRHA</td>
<td>Winnipeg Regional Health Authority</td>
</tr>
</tbody>
</table>
Explanatory Notes and Definitions

Cumulative data
Cumulative data include updates to previous weeks; due to reporting delays or amendments, the sum of weekly report totals may not add up to cumulative totals.

Data extraction date
Manitoba-specific information contained within this report is based on data confirmed at 11:00 am on the date of data extraction.

Epidemiology week
Time trends in this report were analyzed by epidemiology week, a schedule used by the national FluWatch program coordinated by the Public Health Agency of Canada (PHAC).

Incidence rate
Incidence rate measures the frequency with which influenza occurs in a region. It is calculated as the total number of new cases this influenza season multiplied by 100,000 and divided by the total population in each region. Regional populations are based on the Manitoba Health Population Report 2015.

ILI in the general population
Acute onset of respiratory illness with fever and cough and with one or more of the following – sore throat, arthralgia, myalgia, or prostration, which is likely due to influenza. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.

ILI outbreaks
Schools: Greater than 10% absenteeism (or absenteeism that is higher (e.g. >5-10%) than expected level as determined by school or public health authority) which is likely due to ILI.
Hospitals and residential institutions: Two or more cases of ILI within a seven-day period.
Other settings: Two or more cases of ILI within a seven-day period, including at least one laboratory confirmed case; i.e. workplace, closed communities.

Specimen collection date
The date the laboratory specimen was taken is used to assign cases to the epidemiology week in this report. Occasionally, if the specimen collection date is not available, the laboratory report date will be used.

Epidemiology and Surveillance
Manitoba Health, Seniors and Active Living
flusurveillance@gov.mb.ca
(204)786-7335